clinical trial · NCT05869669
RewinD-LB - Clinical Study of Neflamapimod in Patients With Dementia With Lewy Bodies
EIP Pharma Inc·phase2·completed·n = 159
Dementia With Lewy BodiesNeflamapimodPlacebo
brief summary
The purpose of this study is to determine whether neflamapimod can improve learning skills, problem solving skills, and memory loss in people diagnosed with DLB. More specifically, improvement in verbal learning, memory, and attention, as well as cognitive and functional performance will be measured.
started
May 1, 2023
primary completion
May 29, 2025
completion
Jun 16, 2025
last updated
Apr 6, 2026
official title
A Phase 2b Clinical Study of the P38 Alpha Kinase Inhibitor Neflamapimod in Patients With Dementia With Lewy Bodies
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol